

0001171843-24-0053606-K Abivax S.A. 2024092620240926060554060554060554 0 0001171843-24-005360 6-K 2  
20240926 20240926 20240926 Abivax S.A. 0001956827 2834 000000000 IO 1231 6-K 34 001-41842 241326084 7 BD  
HAUSSMANN PARIS IO 75009 01 53 83 09 63 7 BD HAUSSMANN PARIS IO 75009 6-K 1 f6k\_092624.htm FORM 6-K  
À UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF  
FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF  
1934 For the month of September 2024 Commission File Number: 001-41842 Abivax SA (Translation of registrant's name  
into English) 7-11 boulevard Haussmann 75009 Paris, À France +33 (0) 1 53 83 08 41 (Address, including zip code, and  
telephone number, including area code, of registrant's principal executive offices) Indicate by check mark whether the  
registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [X] À À À À À Form 40-F  
[ ] À À On September 26, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit  
99.1 and is incorporated herein by reference. Exhibit Index Exhibit 99.1. À Press release dated September 26,  
2024 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused  
this report to be signed on its behalf by the undersigned, thereunto duly authorized. À À À À À À Abivax  
SA À À À À À À (Registrant) À À À À À À Date: September 26, 2024 À À À À À À /s/ Marc de Garidel À À À À À À Marc de  
Garidel À À Chief Executive Officer À À EX-99.1 2 exh\_991.htm PRESS RELEASE Edgar Filing EXHIBIT 99.1 Abivax to  
Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024 Professor Bruce E. Sands, MD to  
present oral presentation of Phase 2b, open-label, maintenance efficacy and safety data at weeks 48 and 96 among  
week 8 induction non-responders in obefazimod-treated patients with moderately to severely active ulcerative colitis  
(UC) Two moderated poster presentations highlighting corticosteroid-free efficacy and safety data of obefazimod at  
weeks 48 and 96 of an open-label maintenance trial, as well as the impact of obefazimod induction therapy on combined  
histologic and endoscopic outcomes at week 8 in patients with UC PARIS, France, September 26, 2024 à€“ 08:30 a.m.  
CEST à€“ Abivax SA (Euronext Paris: FR0012333284 à€“ ABVX; NASDAQ: ABVX) (à€œAbivaxà€“ or the  
à€œCompanyà€“), a clinical-stage biotechnology company focused on developing therapeutics that harness the  
bodyà€™s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory  
diseases, today announced that three scientific abstracts on its lead drug candidate, obefazimod, will be presented  
during the United European Gastroenterology (UEG) Week meeting, Oct. À 12-15, 2024, in Vienna, Austria. à€œWe look  
forward to returning to UEGW to share new analysis of our Phase 2b trial data on obefazimod in patients with  
moderately to severely active ulcerative colitis,à€“ said Abivax Chief Medical Officer Fabio Cataldi, MD. à€œWith this  
presentation, we have observed additional evidence that obefazimod has the potential to advance the treatment  
paradigm, designed to be a once-daily oral therapy, for people living with ulcerative colitis.à€“ For more information on  
the Abivax clinical program and company updates, please see the conference program at the UEG website. Obefazimod  
data to be presented: Presentation Title Session Presenter Abstract/Poster Number Date/Time of Presentation Oral  
Presentation Efficacy and safety of obefazimod in UC patients at week 48 of an open-label maintenance study among  
clinical non-responders at week 8 of the Phase 2b induction trial IBD New horizons in medical treatment - Part 2 Prof.  
Bruce E. Sands, M.D., M.S. Dr. Burrill B. Crohn Professor of Medicine and Chief, Dr. Henry D. Janowitz Division of  
Gastroenterology, Icahn School of Medicine at Mount Sinai, NY À Tuesday, Oct. 15, 2024, from 11:30 AM to 12:30 PM  
CEST Moderated Poster Presentations Corticosteroid-free efficacy and safety of UC patients receiving once-daily  
obefazimod in an open label 96-week maintenance study among patients who were receiving concomitant  
corticosteroids at induction baseline Small molecules in the treatment of IBD Prof. S  verine Vermeire, MD, PhD. Head  
of the IBD Center at the University Hospitals Leuven, Belgium, and principal investigator in Europe for the study  
programs conducted and ongoing with obefazimod in UC À Tuesday, Oct. 15, 2024, from 14:30 PM to 15:30 PM  
CEST Impact of obefazimod induction therapy on histologic and combined histologic and endoscopic outcomes in  
patients with moderately to severely active ulcerative colitis: week 8 results from the Phase 2b induction trial Small  
molecules in the treatment of IBD Prof. Britta Siegmund, MD, PhD Medical Director, Division of Gastroenterology,  
Infectiology and Rheumatology, Universit  tsmedizin Berlin À Tuesday, Oct. 15, 2024, from 14:30 PM to 15:30 PM  
CEST \*\*\*\*\* About Obefazimod Obefazimod, Abivaxà€™s lead investigational drug candidate, is an orally administered  
small molecule that was demonstrated to potentially enhance the expression of a single microRNA, miR-124. Phase 2  
clinical trials in patients with UC have generated positive data, resulting in the initiation of a pivotal global Phase 3  
clinical trial program (ABTECT Program), with first patients enrolled in the United States in October 2022. Initiation of  
a Phase 2b clinical trial in Crohnà€™s disease is expected in Q3 2024, and exploration of potential combination therapy  
opportunities in UC is ongoing. About Abivax Abivax is a clinical-stage biotechnology company focused on developing  
therapeutics that harness the bodyà€™s natural regulatory mechanisms to stabilize the immune response in patients  
with chronic inflammatory diseases. Based in France and the United States, Abivaxà€™s lead drug candidate,  
obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.  
More information on the Company is available at [www.abivax.com](http://www.abivax.com). Follow us on LinkedIn and X, formerly Twitter,  
@ABIVAX. Contact: Patrick Malloy SVP, Investor Relations Abivax SA [patrick.malloy@abivax.com](mailto:patrick.malloy@abivax.com) +1 847 987 4878  
FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements, forecasts and estimates,  
including those relating to the Companyà€™s business and financial objectives. À Words such as à€œexpect,à€“  
à€œforwardà€“, à€œwillà€“ and variations of such words and similar expressions are intended to identify forward-looking  
statements. À These forward-looking statements include statements concerning or implying the therapeutic potential of  
Abivax's drug candidates, as well as the timing of initiation of a Phase 2b clinical trial of obefazimod in Crohnà€™s  
disease. Although Abivaxà€™s management believes that the expectations reflected in such forward-looking statements  
are reasonable, investors are cautioned that forward-looking information and statements are subject to various À risks,  
contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Abivax, that  
could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the  
forward-looking information and statements. À A description of these risks, contingencies and uncertainties can be  
found in the documents filed by the Company with the French Autorit   des March  s Financiers pursuant to its legal  
obligations including its universal registration document (Document d   Enregistrement Universel) and in our Annual  
Report on Form 20-F filed with the U.S. Securities and Exchange Commission on April 5, 2024 under the caption  
à€œRisk Factors.à€“ These risks, contingencies and uncertainties include among other things, the uncertainties inherent  
in research and development, future clinical data and analysis, decisions by regulatory authorities, such as the FDA or  
the EMA, regarding whether and when to approve any drug candidate, as well as their decisions regarding labelling  
and other matters that could affect the availability or commercial potential of such product candidates. Special  
consideration should be given to the potential hurdles of clinical and pharmaceutical development including further

assessment by the company and regulatory agencies and IRBs/ethics committees following the assessment of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data. Furthermore, these forward-looking statements, forecasts and estimates are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law.Â Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement.Â This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgment. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.